{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:12:25Z","timestamp":1785510745227,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-3045-1","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T19:46:29Z","timestamp":1545853589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7805-5851","authenticated-orcid":false,"given":"Joanna M.","family":"Zakrzewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bendtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik A.","family":"Ettlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine","family":"Maarbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Obermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Morisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deb","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Cruccu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"3045_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1745-6215-7-9","volume":"7","author":"AM McDonald","year":"2006","unstructured":"McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006;7:9.","journal-title":"Trials"},{"key":"3045_CR2","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"28","author":"EF Augustine","year":"2013","unstructured":"Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28:1142\u201350.","journal-title":"J Child Neurol"},{"key":"3045_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13063-016-1322-4","volume":"17","author":"NS Downing","year":"2016","unstructured":"Downing NS, Shah ND, Neiman JH, Aminawung JA, Krumholz HM, Ross JS. Participation of the elderly, women, and minorities in pivotal trials supporting 2011\u20132013 U.S. Food and Drug Administration approvals. Trials. 2016;17:199.","journal-title":"Trials"},{"key":"3045_CR4","unstructured":"U.S. Department of Health and Human Services. Guidance for Industry. E7 studies in support of special populations: geriatrics. Questions and answers. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM189544.pdf\n                    \n                  . Accessed 19 Oct 2017."},{"key":"3045_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40271-014-0096-6","volume":"8","author":"AS Kesselheim","year":"2015","unstructured":"Kesselheim AS, McGraw S, Thompson L, O'Keefe K, Gagne JJ. Development and use of new therapeutics for rare diseases: views from patients, caregivers, and advocates. Patient. 2015;8:75\u201384.","journal-title":"Patient"},{"key":"3045_CR6","doi-asserted-by":"crossref","unstructured":"Fearn P, Avenell A, McCann S, Milne AC, Maclennan G, MAVIS Trial Group. Factors influencing the participation of older people in clinical trials \u2014 data analysis from the MAVIS trial. J Nutr Health Aging. 2010;14:51\u20136.","DOI":"10.1007\/s12603-010-0009-x"},{"key":"3045_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jclinepi.2010.02.007","volume":"64","author":"T Agoritsas","year":"2011","unstructured":"Agoritsas T, Deom M, Perneger TV. Study design attributes influenced patients\u2019 willingness to participate in clinical research: a randomized vignette-based study. J Clin Epidemiol. 2011;64:107\u201315.","journal-title":"J Clin Epidemiol"},{"key":"3045_CR8","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0895-4356(99)00141-9","volume":"52","author":"S Ross","year":"1999","unstructured":"Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol. 1999;52:1143\u201356.","journal-title":"J Clin Epidemiol"},{"key":"3045_CR9","doi-asserted-by":"publisher","first-page":"g6802","DOI":"10.1136\/bmj.g6802","volume":"349","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Thompson L, O\u2019Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802.","journal-title":"BMJ"},{"key":"3045_CR10","unstructured":"International Headache Society. IHS classification ICHD-3. \n                    https:\/\/www.ichd-3.org\/13-painful-cranial-neuropathies-and-other-facial-pains\/13-1-trigeminal-neuralgia\/13-1-1-classical-trigeminal-neuralgia\/\n                    \n                  . Accessed 9 Mar 2018."},{"key":"3045_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pain.2009.08.023","volume":"147","author":"JS Koopman","year":"2009","unstructured":"Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain. 2009;147:122\u20137.","journal-title":"Pain"},{"key":"3045_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.pain.2008.03.002","volume":"137","author":"JP Dieleman","year":"2008","unstructured":"Dieleman JP, Kerklaan J, Huygen FJ, Bouma PA, Sturkenboom MC. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain. 2008;137:681\u20138.","journal-title":"Pain"},{"key":"3045_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ana.410270114","volume":"27","author":"S Katusic","year":"1990","unstructured":"Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945\u20131984. Ann Neurol. 1990;27:89\u201395.","journal-title":"Ann Neurol"},{"key":"3045_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.pain.2006.01.030","volume":"122","author":"GC Hall","year":"2006","unstructured":"Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006;122:156\u201362.","journal-title":"Pain"},{"key":"3045_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/1745-6215-14-402","volume":"14","author":"JM Zakrzewska","year":"2013","unstructured":"Zakrzewska JM, Palmer J, Ettlin DA, Obermann M, Giblin GM, Morisset V, et al. Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia. Trials. 2013;14:402.","journal-title":"Trials"},{"key":"3045_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1474-4422(17)30005-4","volume":"16","author":"JM Zakrzewska","year":"2017","unstructured":"Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, study investigators, et al. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 2017;16:291\u2013300.","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"3045_CR17","first-page":"9","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","unstructured":"Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9\u2013160.","journal-title":"Cephalalgia"},{"key":"3045_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629\u2013808.","journal-title":"Cephalalgia"},{"key":"3045_CR19","volume":"19","author":"J Krischer","year":"2017","unstructured":"Krischer J, Cronholm PF, Burroughs C, McAlear CA, Borchin R, Easley E, et al. Vasculitis Clinical Research Consortium. Experience with direct-to-patient recruitment for enrollment into a clinical trial in a rare disease: a web-based study. J Med Internet Res. 2017;19:e50.","journal-title":"Experience with direct-to-patient recruitment for enrollment into a clinical trial in a rare disease: a web-based study. J Med Internet Res."},{"key":"3045_CR20","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1097\/j.pain.0000000000000853","volume":"158","author":"JM Zakrzewska","year":"2017","unstructured":"Zakrzewska JM, Wu J, Mon-Williams M, Phillips N, Pavitt SH. Evaluating the impact of trigeminal neuralgia. Pain. 2017;158:1166\u201374.","journal-title":"Pain"},{"key":"3045_CR21","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23:129\u201338.","journal-title":"Ann Acad Med Singap"},{"key":"3045_CR22","doi-asserted-by":"crossref","unstructured":"Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Trigeminal neuralgia\u2014a prospective systematic study of clinical characteristics in 158 patients. Headache. 2014;54:1574\u201382.","DOI":"10.1111\/head.12441"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3045-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-3045-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3045-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T19:21:56Z","timestamp":1577388116000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-3045-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3045"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-3045-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As previously provided [], the study was approved by \u201cregulatory authorities and ethics committees in 11 countries: the UK, Germany, Switzerland, Estonia, France, Italy, Latvia, Lithuania, Romania, South Africa and Spain.\u201d In addition, as previously reported [], the phase IIa \u201cstudy protocol, patient information, informed consent forms, and amendments were reviewed and approved by relevant independent ethics committees and institutional review board.\u201d","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JMZ is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre, and has received consulting fees from Convergence Pharmaceuticals Ltd, a Biogen company. JP, VM, and ST were employees of and shareholders in Convergence Pharmaceuticals Ltd, a Biogen company, at the time of the study, and hold stock in Biogen. LB\u2019s institution received payment for conducting the study; however, LB had no personal financial interest and has no other competing interests to declare with regard to this study. GDS and SM have no competing interests to declare. DAE has received financial support from Convergence Pharmaceuticals Ltd, a Biogen company, and Merz. MO has received scientific support and\/or honoraria from Biogen, Convergence Pharmaceuticals Ltd, a Biogen company, Eli Lilly, Genzyme, Heel, Johnson & Johnson, Novartis, Pfizer, Sanofi-Aventis, and Teva; and research grants from Allergan, Electrocore, the German Ministry for Education and Research (BMBF), and Heel. DS was an employee of Biogen at the time of data analysis and manuscript generation and holds stock in Biogen. GC has received financial support and honoraria from Alfasigma, Angelini, and Convergence Pharmaceuticals Ltd, a Biogen company; and has received a research grant from Alfasigma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"704"}}